Ciprofloxacin Lactate IV

Indication : For the treatment of severe infection hospital inpatients who could not be given Ciprofloxacin lactate oral or oral administration is not appropriate. Infections caused by pathogens sensitive to Ciprofloxacin :
– Lower respiratory tract. In the treatment of outpatients with pneumonia due to Pneumococcus, Ciprofloxacin Lactate should not be used as a first choice of drug. Ciprofloxacin Lactate can be regarded as an advisable treatment for pneumonia caused by Klebsiella, Enterobacter, Proteus, Pseudomonas, Haemophilus, Branhamella, Legionella and Staphylococcus.
– Kidney and/or urinary tract.
– Genital organs, including gonorrhoeae and prostatitis.
– Abdominal cavity (e.g. bacterial infections of the gastrointestinal tract, biliary tract, peritonitis).
– Skin and soft tissue.
– Bones and joints.
– Sepsis.
Infections or imminent risk of infection (prophylaxis), patients whose immune system has been weakened (e.g. patient on immunosuppressants or in states of neutropenia). Selective intestinal decontamination in immunosuppressed patients.

Composition : Each 100 ml Ciprofloxacin Lactate IV Infusion 200 mg/100 ml contains Ciprofloxacin lactate equivalent to Ciprofloxacin 200 mg.

Presentation : Ciprofloxacin Lactate IV Infusion 200 mg/100 ml Box, 1 bottle @ 100 ml

On medical prescription only.
Store below 30°C, protect from light.